BLACK WEEKSVials −15% · kits −10% · rest −5%met codeGratis verzending binnen Duitsland vanaf €200

Deze pagina is automatisch vertaald en kan fouten bevatten. Ben je moedertaalspreker? We horen graag je feedback en verbeteringen.Feedback sturen

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), productfoto

Labrapport

PDF
Getest
Getest
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Lab
Analiza Białek
Datum
October 2026
Resultaat
20.34 mg per tablet (20 mg label)
Bestelnr.
Wachtwoord

Onafhankelijk getest, met het wachtwoord direct bij het lab te controleren.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Bestelling

Stukprijs - Gratis verzending binnen Duitsland vanaf €200 tijdens de Black Weeks
  • DHL met tracking
  • Discrete verpakking

4.6 van 5 op Trustpilot73 reviews

In één oogopslag

Tamoxifen (Nolvadex) in cijfers

De kerncijfers uit ons lexicon.

Volledig lexiconartikel
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Kennis

Alles over Tamoxifen (Nolvadex)

FAQ

Veelgestelde vragen

Bronnen bij elk antwoord: lexiconartikel

Nog een vraag?

Schrijf ons, ons team helpt je verder.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Vergelijkingen

Hoe het zich verhoudt

Gerelateerd

Gerelateerde producten